# Veracyte (VCYT) — News

VCYT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vcyt/news

## Recent headlines

- [Trading resumed: NSTR (TXSE)](https://www.ainvest.com/news/trading-resumed-nstr-txse-2610) — AInvest Wire, Oct 2, 2026
  Trading resumed on the Texas Stock Exchange (TXSE) with the resumption of activity for the NSTR symbol, following the exchange’s phased launch earlier in the year. The TXSE, which commenced production trading on July 6 with test securities and transitioned to live trading on July 10, continues to…
- [Veracyte Q2 EPS USD 0.31](https://www.ainvest.com/news/veracyte-q2-eps-usd-0-31-2607) — AInvest Wire, Jul 30, 2026
- [Veracyte outlook 2026 - continues to expect adjusted EBITDA margin to be greater than 26%](https://www.ainvest.com/news/veracyte-outlook-2026-continues-expect-adjusted-ebitda-margin-greater-26-2607) — AInvest Wire, Jul 30, 2026
  Veracyte, Inc. (Nasdaq: VCYT) has reaffirmed its 2026 financial outlook, with expectations that its adjusted EBITDA margin will exceed 26% for the year. This update follows the company’s strong first-quarter performance, which saw total revenue grow by 21% year-over-year to $139.1 million and…
- [Veracyte: outlook 2026 raises testing revenue guidance to $576 million to $582 million](https://www.ainvest.com/news/veracyte-outlook-2026-raises-testing-revenue-guidance-576-million-582-million-2607) — AInvest Wire, Jul 30, 2026
- [Veracyte outlook FY revenue growth 14-15%](https://www.ainvest.com/news/veracyte-outlook-fy-revenue-growth-14-15-2607) — AInvest Wire, Jul 30, 2026
  Veracyte, Inc. (NASDAQ: VCYT) has provided an updated revenue outlook for fiscal year 2026, projecting growth in the range of 14-15% year-over-year. This guidance reflects the company’s continued focus on expanding its genomic testing services and strengthening its market position in oncology…

## Similar Stocks

- [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock
- [GMED](https://www.lighthorse.io/tickers/gmed) — Globus Medical, Inc. Class A Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).